ORTHOCELL LIMITED — Capital/Financing Update 2026

Feb 17, 2026

==> picture [596 x 97] intentionally omitted <==

ASX Announcement

Orthocell Receives $3.0 million R&D Tax Refund

Further strengthens funding capacity to drive the commercialisation of Remplir™

• Orthocell confirms receipt of $3.0 million from the Australian Federal Government’s Research and Development (R&D) Tax Incentive Program.

• Non-dilutive addition to Orthocell’s cash reserves that now stand at $49.6 million following receipt of the R&D tax refund.

• The Company remains focused on driving rapid market adoption of Remplir™, supported by a strong debt-free balance sheet and ongoing investment in clinical evidence and medical education initiatives.

Perth, Australia: 18 February 2026: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has received a Research and Development (R&D) Tax Incentive refund of A$3.0 million for the financial year ended 30 June 2025. Following receipt of the refund, the Company’s cash balance is $49.6 million.

Orthocell CEO and MD, Paul Anderson, said, “Receipt of our R&D tax refund of $3.0 million is a valuable non-dilutive enhancement to our cash position. This Australian Federal Government program should be applauded, as it provides meaningful economic incentives to drive investment in R&D. Our flagship nerve repair product, Remplir, which is now being commercialised throughout the Americas and Asia Pacific, is a tangible example of a product that has benefited from this program.

“We’re in a very strong position to continue to drive the commercialisation of Remplir for the benefit of our shareholders with $49.6 million in cash, no debt and no royalties payable.”

The R&D Tax Incentive is an Australian Government program to encourage innovation by supporting Australian companies to undertake R&D activities in Australia. Under the program, eligible companies can receive cash rebates of up to 48.5% for expenditure on R&D activities.

Orthocell is ultimately targeting a Total Addressable Market in selected jurisdictions of more than US$3.5 billion[1] . The Company remains focused on driving rapid market adoption of Remplir, supported by a strong debt-free balance sheet and ongoing investment in clinical evidence and medical education initiatives.

1 Nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies.

==> picture [596 x 76] intentionally omitted <==

==> picture [596 x 97] intentionally omitted <==

Release authorised by: Paul Anderson Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries Media enquiries Investor enquiries Paul Anderson Haley Chartres Shaun Duffy Orthocell Limited H^CK Director VECTOR Advisors CEO and MD P: +61 8 9360 2888 P: +61 423 139 163 P: +61 404 094 384 E: paul.anderson@orthocell.com E: haley@hck.digital E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company’s flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @Orthocellltd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,” “intend,” “may,” “plan,” “predict,” “project,” “target, ”potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

==> picture [596 x 76] intentionally omitted <==